Porphyromonas gulae is a clinically prevalent,anaerobic,oral bacteria in canines,that may be a causative agent of canine periodontal disease,and a potential threat to human oral health.Research on P.gulae pathogenicit...Porphyromonas gulae is a clinically prevalent,anaerobic,oral bacteria in canines,that may be a causative agent of canine periodontal disease,and a potential threat to human oral health.Research on P.gulae pathogenicity in canines,their owners,and veterinarians is lacking in China.This study aimed to determine the isolation and detec-tion rates of P.gulae in gingival crevicular fluid(GCF)samples from 101 canines in Beijing,using anaerobic culture techniques and 16S rRNA gene sequencing.The main risk factors for the transmission of P.gulae from canines to humans were also analyzed through analyzing the statistical data on risk factor variables from 103 canine owners and 60 veterinarians in Beijing who tested positive for P.gulae detection in GCF samples.The isolation and detection rates of P.gulae in canines were 31.5%(29/92)and 92.1%(93/101),respectively,compared with detection rates of 24.3%(25/103)in canine owners,43.3%(26/60)in veterinarians,and 52.0%(13/25)in dentists.The degree of contact with canines(P=0.001,P<0.01)and smoking(P=0.021,P<0.05)were significant risk factors for P.gulae detection in owners.Moreover,the degree of contact during ultrasonic scaling(P=0.065,0.05<P<0.1)was the most important risk factor for the positive detection of P.gulae in veterinarians.These findings suggest that P.gulae may colonize the human oral cavity through intimate contact with canines or participation in dental ultrasonic scaling operations.展开更多
This study was designed to determine the safety and efficacy of cefovecin (Convenia?;Pfizer Animal Health) when compared to clindamycin (Antirobe?;Pfizer Animal Health) as an adjunctive therapy to periodontal scaling ...This study was designed to determine the safety and efficacy of cefovecin (Convenia?;Pfizer Animal Health) when compared to clindamycin (Antirobe?;Pfizer Animal Health) as an adjunctive therapy to periodontal scaling or surgery for severe periodontal disease in dogs. A multi-centre, double-masked, randomised study was conducted in 299 dogs with severe periodontal disease. Clindamycin, administered once daily at 11 mg/kg bodyweight orally for 10 days following dental surgery was compared with a single, subcutaneous injection of cefovecin (8 mg/kg bodyweight) administered at the time of dental surgery. The primary efficacy parameter assessed was percentage of tooth-root sites bleeding when probed (an indicator of gingival inflammation) 42 days after surgery. Two-hundred and ninety-one (291) dogs were included in the efficacy assessments. Cefovecin was shown to be non-inferior to clindamycin. The percentage of sites bleeding on probing was reduced from 54.3% to 20.3% for the cefovecin group (53.1% reduced to 17.4% for the clindamycin group). There were no suspected adverse drug experiences attributed to treatment with cefovecin or clindamycin. Cefovecin was shown to be as effective and safe adjunctive treatment for severe periodontal disease in dogs undergoing periodontal scaling and surgery as clindamycin.展开更多
The aim of this study was to identify the potential antibacterial effects of gatifloxacin on one of canine periodontal pathogens, Porphyromonas gulae. The minimum inhibitory concentrations (MIC) of gatifloxacin and it...The aim of this study was to identify the potential antibacterial effects of gatifloxacin on one of canine periodontal pathogens, Porphyromonas gulae. The minimum inhibitory concentrations (MIC) of gatifloxacin and its bactericidal effects were investigated. Gatifloxacin inhibited the growth of the canine periodontopathic bacteria tested in broth. An MIC of 50 nM was found to be effective in inhibiting P. gulae. On performing adenosine triphosphate bioluminescence assay, gatifloxacin was found to exhibit bactericidal effects on the tested bacteria in a concentration-dependent manner. The safety of gatifloxacin in mammalian cells was evaluated by assessing the viability of rat bone marrow mesenchymal stem (BMMS) cells treated with gatifloxacin. Almost over 80% of BMMS cells survived after a 3-day culture when treated with 100 nM of gatifloxacin. These results indicate that locally administered gatifloxacin has the potential for being used to prevent canine periodontal infection.展开更多
基金supported by the 14th Five-Year Plan National Key Research and Development Program of China(2022YFD1801104)the National Nature Science Foundation of China(Grant nos.3227190332 and 31972730)+1 种基金the 2115 Talent Development Program of China Agricultural University(Grant no.00109023)the Research Fund(Clinical Diagnosis And Treatment Of Pets)For Young College Teachers In Ruipeng Commonweal Foundation(Grant no.RPJJ2020003).
文摘Porphyromonas gulae is a clinically prevalent,anaerobic,oral bacteria in canines,that may be a causative agent of canine periodontal disease,and a potential threat to human oral health.Research on P.gulae pathogenicity in canines,their owners,and veterinarians is lacking in China.This study aimed to determine the isolation and detec-tion rates of P.gulae in gingival crevicular fluid(GCF)samples from 101 canines in Beijing,using anaerobic culture techniques and 16S rRNA gene sequencing.The main risk factors for the transmission of P.gulae from canines to humans were also analyzed through analyzing the statistical data on risk factor variables from 103 canine owners and 60 veterinarians in Beijing who tested positive for P.gulae detection in GCF samples.The isolation and detection rates of P.gulae in canines were 31.5%(29/92)and 92.1%(93/101),respectively,compared with detection rates of 24.3%(25/103)in canine owners,43.3%(26/60)in veterinarians,and 52.0%(13/25)in dentists.The degree of contact with canines(P=0.001,P<0.01)and smoking(P=0.021,P<0.05)were significant risk factors for P.gulae detection in owners.Moreover,the degree of contact during ultrasonic scaling(P=0.065,0.05<P<0.1)was the most important risk factor for the positive detection of P.gulae in veterinarians.These findings suggest that P.gulae may colonize the human oral cavity through intimate contact with canines or participation in dental ultrasonic scaling operations.
文摘This study was designed to determine the safety and efficacy of cefovecin (Convenia?;Pfizer Animal Health) when compared to clindamycin (Antirobe?;Pfizer Animal Health) as an adjunctive therapy to periodontal scaling or surgery for severe periodontal disease in dogs. A multi-centre, double-masked, randomised study was conducted in 299 dogs with severe periodontal disease. Clindamycin, administered once daily at 11 mg/kg bodyweight orally for 10 days following dental surgery was compared with a single, subcutaneous injection of cefovecin (8 mg/kg bodyweight) administered at the time of dental surgery. The primary efficacy parameter assessed was percentage of tooth-root sites bleeding when probed (an indicator of gingival inflammation) 42 days after surgery. Two-hundred and ninety-one (291) dogs were included in the efficacy assessments. Cefovecin was shown to be non-inferior to clindamycin. The percentage of sites bleeding on probing was reduced from 54.3% to 20.3% for the cefovecin group (53.1% reduced to 17.4% for the clindamycin group). There were no suspected adverse drug experiences attributed to treatment with cefovecin or clindamycin. Cefovecin was shown to be as effective and safe adjunctive treatment for severe periodontal disease in dogs undergoing periodontal scaling and surgery as clindamycin.
文摘The aim of this study was to identify the potential antibacterial effects of gatifloxacin on one of canine periodontal pathogens, Porphyromonas gulae. The minimum inhibitory concentrations (MIC) of gatifloxacin and its bactericidal effects were investigated. Gatifloxacin inhibited the growth of the canine periodontopathic bacteria tested in broth. An MIC of 50 nM was found to be effective in inhibiting P. gulae. On performing adenosine triphosphate bioluminescence assay, gatifloxacin was found to exhibit bactericidal effects on the tested bacteria in a concentration-dependent manner. The safety of gatifloxacin in mammalian cells was evaluated by assessing the viability of rat bone marrow mesenchymal stem (BMMS) cells treated with gatifloxacin. Almost over 80% of BMMS cells survived after a 3-day culture when treated with 100 nM of gatifloxacin. These results indicate that locally administered gatifloxacin has the potential for being used to prevent canine periodontal infection.
